Cargando…

How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections

Nowadays the most important problem in the treatment of bacterial infections is the appearance of MDR (multidrug-resistant), XDR (extensively drug-resistant) and PDR (pan drug-resistant) bacteria and the scarce prospects of producing new antibiotics. There is renewed interest in revisiting the use o...

Descripción completa

Detalles Bibliográficos
Autores principales: Taati Moghadam, Majid, Amirmozafari, Nour, Shariati, Aref, Hallajzadeh, Masoumeh, Mirkalantari, Shiva, Khoshbayan, Amin, Masjedian Jazi, Faramarz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954843/
https://www.ncbi.nlm.nih.gov/pubmed/32021319
http://dx.doi.org/10.2147/IDR.S234353
_version_ 1783486857767550976
author Taati Moghadam, Majid
Amirmozafari, Nour
Shariati, Aref
Hallajzadeh, Masoumeh
Mirkalantari, Shiva
Khoshbayan, Amin
Masjedian Jazi, Faramarz
author_facet Taati Moghadam, Majid
Amirmozafari, Nour
Shariati, Aref
Hallajzadeh, Masoumeh
Mirkalantari, Shiva
Khoshbayan, Amin
Masjedian Jazi, Faramarz
author_sort Taati Moghadam, Majid
collection PubMed
description Nowadays the most important problem in the treatment of bacterial infections is the appearance of MDR (multidrug-resistant), XDR (extensively drug-resistant) and PDR (pan drug-resistant) bacteria and the scarce prospects of producing new antibiotics. There is renewed interest in revisiting the use of bacteriophage to treat bacterial infections. The practice of phage therapy, the application of phages to treat bacterial infections, has been around for approximately a century. Phage therapy relies on using lytic bacteriophages and purified phage lytic proteins for treatment and lysis of bacteria at the site of infection. Current research indicates that phage therapy has the potential to be used as an alternative to antibiotic treatments. It is noteworthy that, whether phages are used on their own or combined with antibiotics, phages are still a promising agent to replace antibiotics. So, this review focuses on an understanding of challenges of MDR, XDR, and PDR bacteria and phages mechanism for treating bacterial infections and the most recent studies on potential phages, cocktails of phages, and enzymes of lytic phages in fighting these resistant bacteria.
format Online
Article
Text
id pubmed-6954843
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69548432020-02-04 How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections Taati Moghadam, Majid Amirmozafari, Nour Shariati, Aref Hallajzadeh, Masoumeh Mirkalantari, Shiva Khoshbayan, Amin Masjedian Jazi, Faramarz Infect Drug Resist Review Nowadays the most important problem in the treatment of bacterial infections is the appearance of MDR (multidrug-resistant), XDR (extensively drug-resistant) and PDR (pan drug-resistant) bacteria and the scarce prospects of producing new antibiotics. There is renewed interest in revisiting the use of bacteriophage to treat bacterial infections. The practice of phage therapy, the application of phages to treat bacterial infections, has been around for approximately a century. Phage therapy relies on using lytic bacteriophages and purified phage lytic proteins for treatment and lysis of bacteria at the site of infection. Current research indicates that phage therapy has the potential to be used as an alternative to antibiotic treatments. It is noteworthy that, whether phages are used on their own or combined with antibiotics, phages are still a promising agent to replace antibiotics. So, this review focuses on an understanding of challenges of MDR, XDR, and PDR bacteria and phages mechanism for treating bacterial infections and the most recent studies on potential phages, cocktails of phages, and enzymes of lytic phages in fighting these resistant bacteria. Dove 2020-01-07 /pmc/articles/PMC6954843/ /pubmed/32021319 http://dx.doi.org/10.2147/IDR.S234353 Text en © 2020 Taati Moghadam et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Taati Moghadam, Majid
Amirmozafari, Nour
Shariati, Aref
Hallajzadeh, Masoumeh
Mirkalantari, Shiva
Khoshbayan, Amin
Masjedian Jazi, Faramarz
How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections
title How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections
title_full How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections
title_fullStr How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections
title_full_unstemmed How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections
title_short How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections
title_sort how phages overcome the challenges of drug resistant bacteria in clinical infections
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954843/
https://www.ncbi.nlm.nih.gov/pubmed/32021319
http://dx.doi.org/10.2147/IDR.S234353
work_keys_str_mv AT taatimoghadammajid howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections
AT amirmozafarinour howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections
AT shariatiaref howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections
AT hallajzadehmasoumeh howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections
AT mirkalantarishiva howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections
AT khoshbayanamin howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections
AT masjedianjazifaramarz howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections